JP6272853B2 - 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 - Google Patents

細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 Download PDF

Info

Publication number
JP6272853B2
JP6272853B2 JP2015521549A JP2015521549A JP6272853B2 JP 6272853 B2 JP6272853 B2 JP 6272853B2 JP 2015521549 A JP2015521549 A JP 2015521549A JP 2015521549 A JP2015521549 A JP 2015521549A JP 6272853 B2 JP6272853 B2 JP 6272853B2
Authority
JP
Japan
Prior art keywords
peptide
active ingredient
cell
conjugate
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015521549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530358A (ja
JP2015530358A5 (OSRAM
Inventor
サン チェ キム
サン チェ キム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2015530358A publication Critical patent/JP2015530358A/ja
Publication of JP2015530358A5 publication Critical patent/JP2015530358A5/ja
Application granted granted Critical
Publication of JP6272853B2 publication Critical patent/JP6272853B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2015521549A 2012-07-11 2013-07-11 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 Active JP6272853B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
KR10-2012-0075444 2012-07-11
KR20120075444 2012-07-11
KR10-2012-0104173 2012-09-19
KR20120104173 2012-09-19
KR10-2012-0109207 2012-09-28
KR20120109207 2012-09-28
KR20130017046 2013-02-18
KR10-2013-0017046 2013-02-18
KR10-2013-0043635 2013-04-19
KR20130043635 2013-04-19
PCT/KR2013/006218 WO2014010971A1 (ko) 2012-07-11 2013-07-11 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물

Publications (3)

Publication Number Publication Date
JP2015530358A JP2015530358A (ja) 2015-10-15
JP2015530358A5 JP2015530358A5 (OSRAM) 2016-09-01
JP6272853B2 true JP6272853B2 (ja) 2018-01-31

Family

ID=49916328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521549A Active JP6272853B2 (ja) 2012-07-11 2013-07-11 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物

Country Status (7)

Country Link
US (1) US10967000B2 (OSRAM)
EP (1) EP2873678B8 (OSRAM)
JP (1) JP6272853B2 (OSRAM)
KR (1) KR101799904B1 (OSRAM)
CN (1) CN104822698B (OSRAM)
ES (1) ES2981865T3 (OSRAM)
WO (1) WO2014010971A1 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3046661T3 (en) 2012-05-11 2025-12-02 Gemvax & Kael Co Ltd Anti-inflammatory peptides and composition comprising the same
KR101997756B1 (ko) 2012-05-11 2019-07-08 주식회사 젬백스앤카엘 패혈증 예방 또는 치료용 조성물
KR102201429B1 (ko) 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
JP6510410B2 (ja) 2012-09-19 2019-05-08 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
BR112015030627A2 (pt) 2013-06-07 2017-07-25 Gemvax & Kael Co Ltd marcadores biológicos úteis na imunoterapia contra o câncer
KR20160039152A (ko) 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
EP3061459B1 (en) 2013-10-23 2019-12-11 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
JP6553605B2 (ja) 2013-11-22 2019-07-31 ジェムバックス アンド カエル カンパニー，リミティド 血管新生抑制活性を有するペプチド、及びそれを含む組成物
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
WO2015167067A1 (ko) 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
WO2016137162A1 (ko) 2015-02-27 2016-09-01 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
ES2879641T3 (es) 2015-05-26 2021-11-22 Gemvax & Kael Co Ltd Octapéptidos antiinflamatorias, antifibróticos y cicatrizantes de heridas y las composiciones que los contienen
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
CN105018499A (zh) * 2015-08-25 2015-11-04 武汉大学 一种抗乙型肝炎病毒的肽核酸及其用途
CN113476589A (zh) * 2015-11-03 2021-10-08 珍白斯凯尔有限公司 肽在制造用于治疗神经退行性疾病的组合物中的用途
KR20180123512A (ko) 2016-04-07 2018-11-16 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
AU2017249218B2 (en) * 2016-04-11 2020-08-27 Arcuate Therapeutics, Inc. Chiral peptides
CN106236695A (zh) * 2016-06-02 2016-12-21 哈尔滨源茂达生物技术有限公司 一种多肽祛痘修复精华液及其制备方法
WO2017211278A1 (en) 2016-06-06 2017-12-14 Asclepiumm Taiwan Co., Ltd Antibody fusion proteins for drug delivery
KR101797167B1 (ko) * 2016-11-09 2017-11-13 주식회사 바이오셀트란 신규의 프로테인 트랜스덕션 도메인 및 이의 용도
CN107759698A (zh) * 2017-09-18 2018-03-06 广东工业大学 一种egfp‑cta2‑tat融合蛋白在制备荧光探针中的应用
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
EP3700548A4 (en) 2017-10-27 2021-07-21 Ohio State Innovation Foundation POLYPEPTIDE CONJUGATES FOR THE INTRACELLULAR DELIVERY OF STONED PEPTIDES
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
CN109553659B (zh) * 2018-11-26 2022-06-21 上海华新生物高技术有限公司 一种细胞穿透肽及透皮干扰素
WO2020130547A1 (ko) * 2018-12-19 2020-06-25 한국화학연구원 인간 엘알알씨24 단백질 유래 세포막 투과 도메인
KR102351041B1 (ko) * 2018-12-19 2022-01-13 한국화학연구원 인간 lrrc24 단백질 유래 세포막 투과 도메인
KR102182985B1 (ko) * 2019-01-03 2020-11-26 주식회사 바이오이즈 pH 의존적 막 투과성 펩타이드를 이용한 약물 운반체 및 그것과 약물의 복합체
CN113950337A (zh) * 2019-01-03 2022-01-18 金圣千 利用pH依赖性细胞膜穿透肽的药物载体以及所述药物载体与药物的复合体
CN114007654A (zh) * 2019-04-17 2022-02-01 阿迪根有限公司 用于分子的细胞内递送的肽和纳米颗粒
EP4058032A4 (en) * 2019-12-19 2024-01-10 Entrada Therapeutics, Inc. Compositions for delivery of antisense compounds
CN115461358A (zh) * 2020-07-17 2022-12-09 养生堂有限公司 一种细胞穿膜肽及其应用
EP4198058A4 (en) * 2020-08-13 2024-10-16 Nibec Co., Ltd. ANTIBODIES AGAINST INTRACELLULAR TUMOR-INDUCING PROTEIN OR FUSION PROTEIN OF A SINGLE-STRANDED VARIABLE FRAGMENT THEREOF AND CANCER CELL PENETRATING PEPTIDE AND USE THEREOF
CN114731988B (zh) * 2022-05-23 2023-10-20 昆明市第一人民医院 一种hbv感染的树鼩模型构建方法及树鼩模型

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207799B (en) 1991-07-24 1993-06-28 Beres Export Import Rt Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis
US5885782A (en) * 1994-09-13 1999-03-23 Nce Pharmaceuticals, Inc. Synthetic antibiotics
CA2632790A1 (en) 1996-07-22 1998-01-29 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
UA74130C2 (uk) 1997-05-15 2005-11-15 Чугаі Сейяку Кабусікі Кайся ЗАСТОСУВАННЯ АНТИТІЛА ПРОТИ БІЛКА, СПОРІДНЕНОГО З ПАРАТИРЕОЇДНИМ ГОРМОНОМ (PTHrP), АБО ЙОГО ФУНКЦІОНАЛЬНО АКТИВНОГО ФРАГМЕНТА І/АБО ЙОГО МОДИФІКОВАНОГО ФРАГМЕНТА ДЛЯ ВИРОБНИЦТВА ЛІКАРСЬКОГО ЗАСОБУ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ КАХЕКСІЇ
AU748442B2 (en) 1997-07-01 2002-06-06 Cambia Vertebrate telomerase genes and proteins and uses thereof
CA2291798A1 (en) * 1998-03-26 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Monoclonal antibody against human telomerase catalytic subunit
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
IL132406A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US7078491B1 (en) * 2000-09-21 2006-07-18 Amgen Inc. Selective binding agents of telomerase
US6815426B2 (en) 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
US6967211B2 (en) 2001-04-10 2005-11-22 Nippon Shinyaku Co. Ltd. Remedial agent for chronic articular rheumatism
JP4502580B2 (ja) 2001-05-16 2010-07-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 敗血症の治療または予防のためのｉｌ−１８阻害剤の使用
US20030143228A1 (en) 2001-10-29 2003-07-31 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
EA007927B1 (ru) 2002-04-10 2007-02-27 Апплайд Резеч Системз Арс Холдинг Н. В. Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
KR20050020987A (ko) 2002-06-12 2005-03-04 바이오겐 아이덱 엠에이 인코포레이티드 아데노신 수용체 길항제를 사용하여 허혈 재관류 손상을치료하는 방법
US20080025986A1 (en) 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
CA2530900A1 (en) 2003-06-25 2004-12-29 Canbas Co., Ltd. Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
KR20050040517A (ko) 2003-10-29 2005-05-03 주식회사 오리엔트 허혈성 질환에 대한 저항성을 나타내는 형질전환 생쥐
DK1530965T3 (da) 2003-11-11 2006-07-17 Mattern Udo Kontrolleret frigivelsesleveringssystem til nasal applikation
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP5273721B2 (ja) 2005-03-21 2013-08-28 ビカス セラピューティクス，エルエルシー 悪液質を緩和するための組成物および方法
EP1967209B1 (en) 2005-11-25 2012-06-06 Keio University Therapeutic agent for prostate cancer
JP2009519033A (ja) 2005-12-16 2009-05-14 ディアト 核酸を細胞に送達するための細胞貫通ペプチド結合体
EP1991560B1 (en) * 2006-02-20 2018-04-04 Ewha University-Industry Collaboration Foundation Peptide having cell membrane penetrating activity
KR101574630B1 (ko) 2006-07-24 2015-12-07 (주)앰브로시아 허혈성 질환의 완화 및 치료를 위한 약학 조성물 및 그를 전달하기 위한 방법
KR20090103957A (ko) 2007-01-29 2009-10-01 주식회사 프로셀제약 신규한 거대분자 전달 도메인 및 이의 동정 방법 및 용도
JP2010532484A (ja) 2007-06-29 2010-10-07 コレロジック システムズ，インコーポレイテッド 卵巣癌のための予測マーカー
WO2009023270A2 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2009025871A1 (en) 2007-08-23 2009-02-26 University Of Medicine And Dentistry Of Nj Telomerase reverse transcriptase variant
EP2212696B1 (en) 2007-10-25 2013-12-04 Genelux Corporation Systems and methods for viral therapy
GB2455539B (en) 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
SI2310044T1 (sl) 2008-06-16 2017-03-31 Mediolanum Farmaceutici S.P.A. Proti-tumorska imunoterapija
US8252282B2 (en) 2008-06-19 2012-08-28 University Of Medicine & Dentistry Of New Jersey Nuclear telomerase reverse transcriptase variant
ES2334315B1 (es) 2008-07-29 2011-02-28 Universitat Pompeu Fabra Peptidos con capacidad de penetracion celular y sus usos.
JP5674661B2 (ja) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
KR20110060940A (ko) 2008-09-22 2011-06-08 닛신 파마 가부시키가이샤 항염증성 펩티드
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
KR101169030B1 (ko) 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
CN102421440B (zh) 2009-05-07 2017-06-09 东国制药（株） 用于预防或治疗神经病理性疼痛的药学组合物
EP2251028A1 (en) 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
US7928067B2 (en) 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
JP5653214B2 (ja) * 2009-05-20 2015-01-14 東レ株式会社 細胞膜透過性ペプチド
KR20110057049A (ko) 2009-11-23 2011-05-31 박의신 기능성 전립선염 치료제
KR20110062943A (ko) 2009-12-04 2011-06-10 주식회사종근당 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
US9657068B2 (en) 2010-02-16 2017-05-23 Ultimovacs As Telomerase polypeptide vaccine for treating cancer
FR2960542B1 (fr) 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
KR101263212B1 (ko) * 2010-05-28 2013-05-10 성신여자대학교 산학협력단 신규한 세포막 투과성 펩타이드 및 그의 용도
WO2011150494A1 (en) 2010-05-30 2011-12-08 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
KR101388372B1 (ko) 2010-06-11 2014-04-23 한국화학연구원 청각보호 작용을 하는 신규 화합물
KR101348284B1 (ko) * 2010-09-09 2014-01-03 주식회사 나이벡 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR20120121196A (ko) 2011-04-26 2012-11-05 주식회사 글루칸 관절염 치료제
KR101284772B1 (ko) 2011-05-24 2013-07-17 정종문 항염증, 진통효과를 가지는 기능성 식품 조성물
KR20120133661A (ko) 2011-05-31 2012-12-11 주식회사 바이오포트코리아 아스타잔틴을 포함하는 항염증제
KR101288053B1 (ko) 2011-07-04 2013-07-23 동국대학교 산학협력단 필발 추출물을 유효성분으로 포함하는 내이손상 예방 및 치료용 조성물
KR101361445B1 (ko) 2011-12-26 2014-02-12 성균관대학교산학협력단 펩타이드, 5-플루오로우라실, 및 성숙수지상세포를 포함하는 암 치료용 약학적 조성물
KR101680164B1 (ko) 2012-02-10 2016-11-28 하쿠신코우세이카이재단 단구 증식제, 단구 증식용 배지, 단구의 제조방법, 수지상 세포의 제조방법, 및 수지상 세포 백신의 제조방법
KR102041381B1 (ko) 2012-03-12 2019-11-27 젬백스 에이에스 능동적인 면역치료법을 이용한 비-소세포성 폐암의 치료
KR101997756B1 (ko) 2012-05-11 2019-07-08 주식회사 젬백스앤카엘 패혈증 예방 또는 치료용 조성물
ES3046661T3 (en) 2012-05-11 2025-12-02 Gemvax & Kael Co Ltd Anti-inflammatory peptides and composition comprising the same
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
EP4230644A3 (en) 2012-09-19 2024-04-24 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
KR102201429B1 (ko) 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
JP6510410B2 (ja) 2012-09-19 2019-05-08 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
KR20140104288A (ko) 2013-02-20 2014-08-28 주식회사 카엘젬백스 Tnf-알파 저해제
PT2959005T (pt) 2013-02-22 2021-12-30 Univ Leland Stanford Junior Utilização médica relacionada com extensão de telómero
KR102258864B1 (ko) 2013-04-19 2021-06-01 주식회사 젬백스앤카엘 허혈성 손상 치료 및 예방용 조성물
BR112015030627A2 (pt) 2013-06-07 2017-07-25 Gemvax & Kael Co Ltd marcadores biológicos úteis na imunoterapia contra o câncer
KR20160039152A (ko) 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
EP3061459B1 (en) 2013-10-23 2019-12-11 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
JP6553605B2 (ja) 2013-11-22 2019-07-31 ジェムバックス アンド カエル カンパニー，リミティド 血管新生抑制活性を有するペプチド、及びそれを含む組成物
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
US9937240B2 (en) 2014-04-11 2018-04-10 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
WO2015167067A1 (ko) 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
WO2016137162A1 (ko) 2015-02-27 2016-09-01 주식회사 젬백스앤카엘 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물
CN113476589A (zh) 2015-11-03 2021-10-08 珍白斯凯尔有限公司 肽在制造用于治疗神经退行性疾病的组合物中的用途
KR20170054310A (ko) 2015-11-09 2017-05-17 주식회사 젬백스앤카엘 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법

Also Published As

Publication number Publication date
WO2014010971A1 (ko) 2014-01-16
JP2015530358A (ja) 2015-10-15
EP2873678B1 (en) 2024-06-26
EP2873678C0 (en) 2024-06-26
US20160151512A1 (en) 2016-06-02
ES2981865T3 (es) 2024-10-10
US10967000B2 (en) 2021-04-06
CN104822698A (zh) 2015-08-05
KR101799904B1 (ko) 2017-11-22
EP2873678A4 (en) 2016-05-18
EP2873678B8 (en) 2024-07-17
EP2873678A1 (en) 2015-05-20
CN104822698B (zh) 2018-08-10
KR20150034746A (ko) 2015-04-03

Similar Documents

Publication Publication Date Title
JP6272853B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP7627726B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP7742390B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP6510410B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
TWI616530B (zh) 穿膜胜肽以及包含該胜肽之共軛物及組成物（一）

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180104

R150 Certificate of patent or registration of utility model

Ref document number: 6272853

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250